Mendus AB, co-located in Sweden and the Netherlands, has appointed the oncology specialist Tariq Mughal as chief medical officer to help direct the late stage development and registration of vididencel, a treatment for acute myeloid leukaemia. Dr Mughal joins from Stemline Therapeutics Inc, part of the Menarini Group, where he led clinical drug development. Before that, he was vice president of clinical and medical affairs at Foundation Medicine Inc, an affiliate of the Roche Group. He is also clinical professor of medicine at the Tufts University Cancer Centre in Boston, US.
Mendus announced the appointment on 5 May 2025.
Copyright 2025 Evernow Publishing Ltd